| |
Entecavir at Five Years Shows Long Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance
|
| |
| |
Reported by Jules Levin
This data was presented today at 18th Conference of the Asia-Pacific Association for the Study of the Liver (APASL) in Seoul, Korea.
D.J. Tenney Tenney1, K.A. Pokorowski , Pokorowski1, R.E. Rose , Rose1,
C.J. Baldick Baldick1, B.J. Eggers , Eggers1, J. Fang , Fang1, J.Y. Yang , Yang1, D. Xu Xu1, , H. Brett Brett-Smith Smith1 & R.J. Colonno Colonno2
1Research and Development, Bristol Research Bristol-Myers Squibb Company, United States; 2Formerly of Bristol Formerly Bristol-Myers Squibb Company Company, United States.
AUTHOR SUMMARY
Entecavir Resistance Through 5 Years
Nucleoside Naive:
--ETV has high potency and high genetic barrier
--Resistance is rare through 5 years
1.2% genotypic resistance
LVD refractory:
--ETV potency and genetic barrier are reduced
--Incremental increase in resistance over time
Yokosuka, et al. Abstract FP 067:
Year data from Japan consistent with above
|
|
| |
| |
|
|
|
